# PDUFA dates November 2027: FDA calendar and catalysts

Canonical: https://sec-api.dev/fda-calendar/2027-11

> 30 FDA catalysts are dated in November 2027, including 1 PDUFA date.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What PDUFA dates are in November 2027?

PDUFA dates in November 2027: deramiocel (CAPR) on November 22, 2027. [Calendar and source filings](https://sec-api.dev/fda-calendar/2027-11)

Source: SEC Form 10-Q, accession 0001104659-26-125355, https://www.sec.gov/Archives/edgar/data/1133869/000110465926125355/capr-20260930x10q.htm (retrieved 2026-11-12). Last confirmed 2026-11-10. Cite: https://sec-api.dev/fda-calendar/2027-11#answer

## PDUFA dates in November 2027

Data as of November 16, 2026.

| PDUFA date | Company | Ticker | Drug | Indication | Source |
| --- | --- | --- | --- | --- | --- |
| November 22, 2027 | CAPRICOR THERAPEUTICS, INC. | CAPR | deramiocel |  | [SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1133869/000110465926125355/capr-20260930x10q.htm) |

## All catalysts in November 2027

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| November 2027 | [Truqap (capivasertib) primary completion](https://sec-api.dev/pdufa/capivasertib) | AZN | Locally Advanced (Inoperable) or Metastatic Breast Cancer | scheduled | "NCT04862663 (Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-11-01 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04862663)) |
| November 2027 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | NSCLC | scheduled | "NCT05687266 (Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-11-01 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05687266)) |
| November 2027 | [Tozorakimab primary completion](https://sec-api.dev/pdufa/tozorakimab) | AZN | Viral Lung Infection and Acute Respiratory Failure | scheduled | "NCT05624450 (Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-11-04 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05624450)) |
| November 2027 | [Opevesostat primary completion](https://sec-api.dev/pdufa/opevesostat) | MRK | Malignant Neoplasm | scheduled | "NCT06979596 (A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11-04 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06979596)) |
| November 2027 | [Wayrilz (rilzabrutinib) primary completion](https://sec-api.dev/pdufa/rilzabrutinib) | SNY | Immune Thrombocytopenia | scheduled | "NCT07007962 (Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-11-05 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07007962)) |
| November 2027 | [Risvutatug rezetecan (ris-rez) primary completion](https://sec-api.dev/pdufa/risvutatug-rezetecan-ris-rez) | GSK | Neoplasms, Lung | scheduled | "NCT07099898 (A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-11-05 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07099898)) |
| November 2027 | [Wegovy (semaglutide) primary completion](https://sec-api.dev/pdufa/semaglutide) | NVO | Diabetes Mellitus, Type 2 | scheduled | "NCT03811561 (A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-11-07 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03811561)) |
| November 2027 | [Sonesitatug vedotin primary completion](https://sec-api.dev/pdufa/sonesitatug-vedotin) | AZN | Gastroesophageal Adenocarcinoma | scheduled | "NCT07069712 (A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11-09 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07069712)) |
| November 2027 | [AZD1163 primary completion](https://sec-api.dev/pdufa/azd1163) | AZN | Rheumatoid Arthritis | scheduled | "NCT07276581 (A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11-12 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07276581)) |
| November 13, 2027 | [INTEGRATED BIOPHARMA INC interim data readout](https://sec-api.dev/companies/inbp/catalysts) | INBP |  | scheduled | "After taking into consideration our interim results and current projections, management believes that operations, together with the revolving credit facility will support our working capital requirements at least through the period ending November 13, 2027." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1016504/000143774926036725/inbp20260930_10q.htm)) |
| November 2027 | [Exagamglogene autotemcel primary completion](https://sec-api.dev/pdufa/exagamglogene-autotemcel) | VRTX | Beta-Thalassemia; Thalassemia; Genetic Diseases, Inborn | scheduled | "NCT05356195 (Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-11-14 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05356195)) |
| November 2027 | [Bel-sar primary completion](https://sec-api.dev/pdufa/bel-sar) | AURA | Choroidal Melanoma; Indeterminate Lesions; Uveal Melanoma | scheduled | "NCT06007690 (A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-11-15 (ESTIMATED); Lead Sponsor Aura Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06007690)) |
| November 2027 | [Zenbexus (iberdomide hydrochloride) primary completion](https://sec-api.dev/pdufa/iberdomide) | BMY | Multiple Myeloma | scheduled | "NCT04975997 (Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-11-16 (ESTIMATED); Lead Sponsor Celgene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04975997)) |
| November 2027 | [SKYCLARYS® (omaveloxolone) primary completion](https://sec-api.dev/pdufa/omaveloxolone) | BIIB | Friedreich Ataxia | scheduled | "NCT06953583 (A Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (BIIB141) in Children and Teens With Friedreich's Ataxia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-11-16 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06953583)) |
| November 2027 | [CDR132L primary completion](https://sec-api.dev/pdufa/cdr132l) | NVO | Heart Failure | scheduled | "NCT06979362 (A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11-16 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06979362)) |
| November 2027 | [Pasritamig primary completion](https://sec-api.dev/pdufa/pasritamig) | JNJ | Prostatic Neoplasms, Castration-Resistant | scheduled | "NCT07225946 (A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-11-19 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07225946)) |
| November 22, 2027 | [Deramiocel PDUFA date](https://sec-api.dev/pdufa/deramiocel) | CAPR |  | scheduled | "Following the FDA's extension of the PDUFA target action date to November 22, 2026, the Company updated its estimated contractual and rent commencement dates to November 22, 2026 and November 22, 2027, respectively, and remeasured the lease, resulting in an increase to the lease liability and the ROU asset of approximately $73,000." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1133869/000110465926125355/capr-20260930x10q.htm)) |
| November 2027 | [Rina-s primary completion](https://sec-api.dev/pdufa/rina-s) | GMAB | Non-small Cell Lung Cancer (NSCLC) | scheduled | "NCT07288177 (Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11-22 (ESTIMATED); Lead Sponsor Genmab." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07288177)) |
| November 2027 | [Vonvendi primary completion](https://sec-api.dev/pdufa/vonvendi) | TAK | Von Willebrand Disease (VWD) | scheduled | "NCT07129343 (A Study of Recombinant Von Willebrand Factor (rVWF) in Chinese Participants With Von Willebrand Disease (vWD)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-11-25 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07129343)) |
| November 2027 | [Volrustomig primary completion](https://sec-api.dev/pdufa/volrustomig) | AZN | Locally Advanced Cervical Cancer | scheduled | "NCT06079671 (Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-11-26 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06079671)) |
| November 2027 | [GSK4532990 primary completion](https://sec-api.dev/pdufa/gsk4532990) | GSK | Liver Diseases, Alcoholic | scheduled | "NCT06613698 (A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11-26 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06613698)) |
| November 2027 | [BMS-986368 primary completion](https://sec-api.dev/pdufa/bms-986368) | BMY | Agitation; Alzheimer Disease | scheduled | "NCT06808984 (Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11-26 (ESTIMATED); Lead Sponsor Celgene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06808984)) |
| November 2027 | [Lipfendra (enlicitide decanoate) primary completion](https://sec-api.dev/pdufa/enlicitide-decanoate) | MRK | Hyperlipidemia; Hypercholesterolemia | scheduled | "NCT07821944 (A Clinical Study of Enlicitide (MK-0616) in Adults With Hyperlipidemia in India (MK-0616-038)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-11-26 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07821944)) |
| November 2027 | [FABHALTA® (iptacopan) primary completion](https://sec-api.dev/pdufa/iptacopan) | NVS | Glomerulonephritis, IGA; Immunoglobulin A Nephropathy | scheduled | "NCT06797518 (Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11-27 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06797518)) |
| November 2027 | [TAK-360 primary completion](https://sec-api.dev/pdufa/tak-360) | TAK | Narcolepsy Type 1 | scheduled | "NCT07633301 (A Study of TAK-360 in Adults With Narcolepsy Type 1 (Narcolepsy With Cataplexy)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11-28 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07633301)) |
| November 2027 | [Velzatinib primary completion](https://sec-api.dev/pdufa/velzatinib) | GSK | Gastrointestinal Neoplasms | scheduled | "NCT07689201 (A Study of Velzatinib in Participants With Metastatic and/or Unresectable GIST After Imatinib, Sunitinib, Regorafenib, and Pimitespib): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11-29 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07689201)) |
| November 2027 | [AZD0901 primary completion](https://sec-api.dev/pdufa/azd0901) | AZN | Gastric Cancer | scheduled | "NCT05702229 (Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11-30 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05702229)) |
| November 2027 | [Faslodex (fulvestrant) primary completion](https://sec-api.dev/pdufa/fulvestrant) | AZN | Locally Advanced or Metastatic Breast Cancer | scheduled | "NCT06764186 (A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-11-30 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06764186)) |
| November 2027 | [Ultomiris® (ravulizumab) primary completion](https://sec-api.dev/pdufa/ravulizumab) | AZN | Delayed Graft Function; DGF; Kidney Transplant | scheduled | "NCT06830798 (Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-11-30 (ESTIMATED); Lead Sponsor Alexion Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06830798)) |
| November 2027 | [Sirna primary completion](https://sec-api.dev/pdufa/sirna) | ADRX | Hereditary Angioedema; HAE; Hereditary Angioedema - Type 1 | scheduled | "NCT06960213 (STOP-HAE: A Phase 3 Study of ADX-324 in HAE): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-11-30 (ESTIMATED); Lead Sponsor ADARx Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06960213)) |

Other months: https://sec-api.dev/fda-calendar/2027-10 , https://sec-api.dev/fda-calendar/2027-12. Calendar: https://sec-api.dev/fda-calendar

## Feeds and downloads

- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PDUFA dates November 2027: FDA calendar and catalysts." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/fda-calendar/2027-11

```bibtex
@misc{secapidev_fda_calendar_2027_11_20261116,
  title        = {PDUFA dates November 2027: FDA calendar and catalysts},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/fda-calendar/2027-11}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_fda_calendar_2027_11_20261116","title":"PDUFA dates November 2027: FDA calendar and catalysts","publisher":"sec-api.dev","URL":"https://sec-api.dev/fda-calendar/2027-11","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
